These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 28126468)

  • 1. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    Farquhar MJ; Humphreys IS; Rudge SA; Wilson GK; Bhattacharya B; Ciaccia M; Hu K; Zhang Q; Mailly L; Reynolds GM; Ashcroft M; Balfe P; Baumert TF; Roessler S; Wakelam MJO; McKeating JA
    J Hepatol; 2017 May; 66(5):919-929. PubMed ID: 28126468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C.
    Takemura K; Takizawa E; Tamori A; Nakamae M; Kubota H; Uchida-Kobayashi S; Enomoto M; Kawada N; Hino M
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration.
    Wilson GK; Brimacombe CL; Rowe IA; Reynolds GM; Fletcher NF; Stamataki Z; Bhogal RH; Simões ML; Ashcroft M; Afford SC; Mitry RR; Dhawan A; Mee CJ; Hübscher SG; Balfe P; McKeating JA
    J Hepatol; 2012 Apr; 56(4):803-9. PubMed ID: 22178269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation.
    Kostadinova L; Shive CL; Anthony DD
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31769428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
    Trovato FM; Zia R; Napoli S; Wolfer K; Huang X; Morgan PE; Husbyn H; Elgosbi M; Lucangeli M; Miquel R; Wilson I; Heaton ND; Heneghan MA; Auzinger G; Antoniades CG; Wendon JA; Patel VC; Coen M; Triantafyllou E; McPhail MJ
    Hepatology; 2021 Aug; 74(2):907-925. PubMed ID: 33908067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels.
    Enooku K; Uranbileg B; Ikeda H; Kurano M; Sato M; Kudo H; Maki H; Koike K; Hasegawa K; Kokudo N; Yatomi Y
    PLoS One; 2016; 11(9):e0161825. PubMed ID: 27583415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity.
    Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Tomiya T; Tejima K; Nishikawa T; Arai M; Yanase M; Aoki J; Arai H; Omata M; Fujiwara K; Yatomi Y
    Life Sci; 2007 Sep; 81(12):1009-15. PubMed ID: 17850827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte autotaxin expression promotes liver fibrosis and cancer.
    Kaffe E; Katsifa A; Xylourgidis N; Ninou I; Zannikou M; Harokopos V; Foka P; Dimitriadis A; Evangelou K; Moulas AN; Georgopoulou U; Gorgoulis VG; Dalekos GN; Aidinis V
    Hepatology; 2017 Apr; 65(4):1369-1383. PubMed ID: 27981605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.
    Takemura K; Takizawa E; Tamori A; Nakamae M; Kubota H; Uchida-Kobayashi S; Enomoto M; Kawada N; Hino M
    J Gastroenterol Hepatol; 2021 Jan; 36(1):217-224. PubMed ID: 32453907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma.
    Kondo M; Ishizawa T; Enooku K; Tokuhara Y; Ohkawa R; Uranbileg B; Nakagawa H; Tateishi R; Yoshida H; Kokudo N; Koike K; Yatomi Y; Ikeda H
    Clin Chim Acta; 2014 Jun; 433():128-34. PubMed ID: 24642343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
    Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Aoki J; Hama K; Okudaira S; Tanaka M; Tomiya T; Yanase M; Tejima K; Nishikawa T; Arai M; Arai H; Omata M; Fujiwara K; Yatomi Y
    J Clin Gastroenterol; 2007 Jul; 41(6):616-23. PubMed ID: 17577119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
    Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
    J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.
    Laface C; Ricci AD; Vallarelli S; Ostuni C; Rizzo A; Ambrogio F; Centonze M; Schirizzi A; De Leonardis G; D'Alessandro R; Lotesoriere C; Giannelli G
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATX‑LPA axis facilitates estrogen‑induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway.
    Zhang G; Cheng Y; Zhang Q; Li X; Zhou J; Wang J; Wei L
    Mol Med Rep; 2018 Mar; 17(3):4245-4252. PubMed ID: 29328374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
    Schmid R; Wolf K; Robering JW; Strauß S; Strissel PL; Strick R; Rübner M; Fasching PA; Horch RE; Kremer AE; Boos AM; Weigand A
    BMC Cancer; 2018 Dec; 18(1):1273. PubMed ID: 30567518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.
    Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M
    Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development.
    Valdés-Rives SA; González-Arenas A
    Mediators Inflamm; 2017; 2017():9173090. PubMed ID: 29430083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autotaxin determines colitis severity in mice and is secreted by B cells in the colon.
    Lin S; Haque A; Raeman R; Guo L; He P; Denning TL; El-Rayes B; Moolenaar WH; Yun CC
    FASEB J; 2019 Mar; 33(3):3623-3635. PubMed ID: 30481488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autotaxin and chronic inflammatory diseases.
    Magkrioti C; Galaris A; Kanellopoulou P; Stylianaki EA; Kaffe E; Aidinis V
    J Autoimmun; 2019 Nov; 104():102327. PubMed ID: 31471142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
    Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
    Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.